Drug Database
FL

fluticasone propionate

✓ Approved

Cantabria Labs · NR3C1 · Small Molecule

What is fluticasone propionate?

fluticasone propionate is a small molecule developed by Cantabria Labs. It is approved for therapeutic indications via topical.

Drug Profile

CompanyCantabria Labs
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Cantabria Labs

Mechanism of Action

Molecular Targets

fluticasone propionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

fluticasone propionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
InvestigationsDermatologic examination✓ Approved

Related Research Articles

PubMedThe Journal of dermatology2026-07-25

Topical Cycling and Systemic Eligibility in Patients With Psoriasis in Japan.

Morita Akimichi A, Imafuku Shinichi S, Torii Hideshi H, Peetluk Lauren L et al.

Topical therapy is the typical first-line treatment for psoriasis, with the International Psoriasis Council recommending systemic therapy for patients with body surface area > 10%, high-impact site involvement, or topical therapy failure. A recent Japanese Delphi Consensus Study proposed a definition for topical failure that considers time on therapy, failure to respond, flare on therapy, and other concepts. Using 2 real-world data sources, this study aimed to describe topical cycling and evaluate systemic therapy eligibility among patients with psoriasis in Japan. With DeSC insurance claims data (January 1, 2017, to August 31, 2024), we evaluated topical therapy treatment patterns before systemic treatment initiation. With data from the Japanese subgroup of the UPLIFT survey, we applied recommendations from the Japan Delphi Study to estimate the proportion of patients receiving topical therapy who may be eligible for systemic treatment. Of 6361 patients with psoriasis from the DeSC database, at least 1 dispensing of a topical therapy (index event) and no systemic treatment at index, 9.5% initiated systemic therapy during follow-up (mean time to initiation 712.5 days). Most patients began with strong/very strong corticosteroids (35.0%) or combinations of topical therapies (± vitamin D; 41.8%), with a shift toward predominantly combination regimens during follow-up. Most patients received multiple topical therapy classes before initiating systemic therapy (mean unique classes: 3.8). Of 137 Japanese UPLIFT survey respondents with psoriasis with or without psoriatic arthritis using only topical therapy, 92.7% met at least 1 of the 7 Delphi consensus recommendations assessed, indicating potential eligibility for systemic treatment; 87.6% met more than 1 recommendation and 57.7% met 3 or more. Our findings suggest that many Japanese adults with psoriasis who may be eligible for systemic therapy may be undertreated and highlight the need to apply eligibility criteria for systemic treatment in clinical practice, which could improve long-term patient outcomes.

PMID 42499214
Read full article →
PubMedEFSA journal. European Food Safety Authority2026-07-25

Safety of the feed additive consisting of chromium propionate (KemTRACE Chromium 0.4% MT) for chickens for fattening, chickens reared for laying/reproduction, turkeys for fattening and turkeys reared for reproduction (Kemin Europa N.V.).

EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Villa Roberto Edoardo RE, Azimonti Giovanna G, Bonos Eleftherios E et al.

An assessment of the safety and efficacy of a feed additive consisting of chromium propionate (KemTRACE™ Chromium) was issued on 18 March 2021. Due to difficulties in implementing the proposed method for the official control of added organic chromium in premixtures and feed, the additive needed incorporating a tracer in the composition of a premix. The European Commission asked EFSA to issue a new opinion on the safety and efficacy of Cr propionate (KemTRACE™ Chromium) as a feed additive for all growing poultry species, including the newly submitted information by the applicant that involves the use of the microtracer. In the FEEDAP Panel opinion on the safety of the microtracer issued on 15 January 2025, no conclusion could be made on the environmental safety of the microtracer for the groundwater compartment. Following the request from the applicant and its acceptance by the European Commission, as indicated in its letter to EFSA of 12 January 2026, the scope of the current assessment has been modified to consider a change in the additive under assessment and a reduction of the target species. Therefore, EFSA delivers an assessment of the safety and efficacy of the additive consisting of Cr propionate (KemTRACE chromium 0.4% MT) for chickens for fattening, chickens reared for laying/reproduction, turkeys for fattening and turkeys reared for reproduction. The use of KemTRACE Chromium 0.4% MT (containing a microtracer) at the proposed conditions of use is safe for the target species, consumers and the environment. The additive is considered irritant to the eyes and a dermal and respiratory sensitiser. Exposure of users by any route is considered a risk. KemTRACE Chromium 0.4% MT has the potential to be efficacious as a zootechnical additive in chickens for fattening, chickens reared for laying/reproduction, turkeys for fattening and turkeys reared for reproduction at the supplementation level of 0.4 mg Cr/kg feed.

PMID 42499334
Read full article →
PubMedCureus2026-07-25

Economic Burden and Cost Differences Between Branded and Generic Topical Antifungals in India.

Dt Prateek P, Dongerkery Kavitha K, Deolekar Pradnya P, Dahibhate Atharva A et al.

India's pharmaceutical market is characterized by a significant presence of both generic and branded drugs, particularly for common ailments such as superficial mycoses (SFMs), which pose a substantial public health and economic burden. Patients in tropical countries like India, which have common superficial mycoses, need prolonged treatment because of their recurrence rates after initial treatment and due to incomplete therapy. Given the high variability in drug pricing and the imperative for cost-effective healthcare, a pharmacoeconomic analysis comparing generic and branded topical antifungals in India is crucial to inform prescribing practices and optimize resource allocation. The price comparison of various topical antifungal medications from different brands was conducted by using the latest information from the "Monthly Index of Medical Specialties" August to October 2025, and 1mg online pharmacy and Jan Aushadhi website. The study calculated the total expenses for 30 mL and 30 g dosage forms, which included cream, ointment, lotion, eye drops, and shampoo products of each drug brand. We conducted a comparison between different drug brands through their cost ratio, and percentage cost variation (PCV) analysis was done, keeping generic medicines prices (retrieved from the Jan Aushadhi website) as baseline values. The data analysis showed a significant variation in the costs of different brands of topical antifungals in the Indian market. After analysis, we identified itraconazole 1% ointment to have the highest cost variation at 8335.1%, followed by clotrimazole dusting powder (4740%). Ketoconazole 2% cream, bifonazole 1% lotion, and sertaconazole shampoo showed the smallest variation at 3.29%, 3.5%, and 11.3%, respectively. When generic and branded topical antifungals were compared, the highest cost variation was seen for clotrimazole 1% cream (3431.7%), and the least variation was observed for ketoconazole 2% powder (135.4%). When combination topical antifungals were compared, the highest percentage cost variation of 1479.4% was seen for clotrimazole 1%w/w and beclomethasone dipropionate 0.025%w/w cream, and the least percentage cost variation of 38.8% was seen for terbinafine (1% w/w) + ciprofloxacin (1% w/w) + metronidazole (1% w/w) + clobetasol (0.05% w/w). The market for topical antifungal agents demonstrates substantial price variation among available products. Regulatory authorities, pharmaceutical manufacturers, and clinicians must collaborate to achieve optimal reductions in drug costs. Strict implementation of cost regulation policies, along with increased awareness among clinicians regarding the rational selection of cost-effective therapies, is essential.

PMID 42500790
Read full article →
PubMedBiomaterials research2026-07-25

Tryptanthrin Nanoliposomal Lotion as a Corticosteroid-Free Strategy for Safe and Effective Treatment of Atopic Dermatitis.

Song Yo Han YH, Na Young-Guk YG, Yoon Moon Sup MS, Kim Da-Eun DE et al.

Atopic dermatitis is a chronic inflammatory skin disease characterized by dry skin, itching, and recurrent eczematous lesions. Although current therapeutic strategies are effective, their use is often limited due to adverse effects. Therefore, the development of safer and more effective alternatives is required. Tryptanthrin is a yellow-gold alkaloid compound with anti-atopic and various pharmacological activities. However, its poor aqueous solubility results in low topical bioavailability. A tryptanthrin-loaded liposomal lotion was developed using a design of experiments approach to improve topical delivery. The optimized formulation showed enhanced physicochemical stability and moisturizing properties, as well as improved drug release compared to free tryptanthrin. In human keratinocyte cells, the liposomal lotion exhibited lower cytotoxicity than the free tryptanthrin and demonstrated higher skin residual. In the DNCB-induced atopic dermatitis mouse model, the tryptanthrin-loaded liposomal lotion produced therapeutic effects comparable to or greater than those of 1.0% hydrocortisone, without inducing adverse effects such as skin atrophy. Overall, the tryptanthrin-loaded liposomal lotion is presented as a promising and safe strategy for the topical treatment of atopic dermatitis.

PMID 42499629
Read full article →
PubMedCase reports in dermatology2026-07-25

High-Potency Depigmenting Mask Delivered via 1,927-nm Fractional Laser in Refractory Melasma: A Pilot Case Series.

Piquero-Casals Jaime J, Mir-Bonafé Juan Francisco JF, Rozas-Muñoz Eduardo E, Piquero-Casals Vanesa V et al.

Melasma is a chronic, relapsing hyperpigmentation disorder and may remain refractory despite multiple topical agents and procedural approaches. We report a case series of six women with Fitzpatrick skin types III-V and longstanding, treatment-resistant facial melasma managed with a multimodal protocol consisting of (1) a 16-week home regimen (twice-daily depigmenting cosmeceutical serum and daily high-protection sunscreen) and (2) two sessions of low-energy, low-density 1,927-nm fractional thulium laser at 4-week intervals, immediately followed by laser-assisted delivery of a compounded depigmenting mask (hydroquinone, retinoic acid, kojic acid, triamcinolone acetonide, vitamins C and E). Clinical response was assessed using the Melasma Severity Scale (MSS), standardized photography, and patient satisfaction. At week 16, all patients improved: 4 achieved >75% clinical improvement and 2 achieved 50-75% improvement, with high satisfaction and no significant adverse events beyond transient darkening and mild desquamation. Clinical benefits remained stable 12 weeks after the final laser session. This case series suggests that 1,927-nm fractional thulium laser-assisted delivery of a high-potency depigmenting compound, supported by topical priming and strict photoprotection, may be a feasible option for selected patients with refractory melasma.

PMID 42499700
Read full article →
PubMedHealth care science2026-07-25

Management of Radiodermatitis in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Scoping Review.

da Silva Tâmara Taynah Medeiros TTM, Silva Louise Constancia de Melo Alves LCMA, de Lima Fernandes Thatiane Evelyn TE, Leal Karena Cristina da Silva KCDS et al.

Given the worldwide prevalence of head and neck cancer and the importance of scientifically based treatment, current studies are discussing innovative strategies for the treatment of radiodermatitis. This review adhered to the Joanna Briggs Institute's nine-step methodological framework for scoping reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews checklist. We searched eight databases: Web of Science, Science Direct, Scientific Electronic Library Online, CAPES Catalog of Theses and Dissertations, Elsevier's Scopus, Wiley Online Library, PubMed Central, and Cochrane Library. Data collection occurred in March 2024. A final sample of 21 articles was selected. The research question was formulated using the "Population, Concept and Context" framework. This led to the specific question: "What are the strategies identified in the literature used in the management of radiodermatitis in patients with head and neck cancer undergoing radiotherapy?" The included studies were published between 2011 and 2024, with China being the leading producer of articles. Clinical trials were the predominant study design. Scales were frequently used to assess various aspects of radiodermatitis. The Radiation Therapy Oncology Group criteria were commonly used. Several topical agents for preventing radiodermatitis were evaluated, including pharmacological therapies, phototherapy/photobiomodulation, and dressings. Numerous topical agents have been clinically tested for the treatment and prevention of radiodermatitis in patients with head and neck cancer. However, the current body of research is insufficient in both quantity and quality to conclusively support or refute the widespread approval of any specific product.

PMID 42499639
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about fluticasone propionate